The groundbreaking ceremony for the BioNTech vaccine manufacturing facility in Rwanda is presided over by President Paul Kagame.
The Rwandan government and BioNTech have been collaborating on the development of a cutting-edge mRNA-based vaccine manufacturing facility.
“Everyone anticipates the factory’s opening. The Health Minister, Dr. Sabin Nsanzimana, stated that before the year ends, operations in vaccine research and manufacturing will begin.
The process of creating vaccines is a time-consuming one, therefore production will not begin immediately.
A BioNTech plant was established in the Gasabo District Special Economic Zone following the signing of a memorandum of agreement between the two parties.
The factory is finally ready, having spent months of intense labor shipping and installing BioNTainers, which are facilities capable of producing a variety of mRNA-based vaccinations.
The building in Rwanda has a total floor space of roughly 30,000 square meters. It has BioNTainers installed (for mRNA synthesis and prepared bulk medicinal products).
50 million vaccines should be produced at the plant in the beginning, although output will rise or fall according on demand.
The facility is anticipated by BionTech to become Africa’s first node in a robust and decentralized end-to-end manufacturing network.
In order to facilitate access to innovative medications, vaccines from such infrastructures will be aimed for residents of African Union member states.
BioNTech is using its mRNA platform to advance mRNA-based vaccine candidates against tuberculosis and malaria.